- Home
- BCAB vs GEG Comparison
BCAB vs GEG Comparison
Compare BCAB & GEG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | BCAB | GEG |
|---|---|---|
| Founded | 2007 | 1994 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Medicinal Chemicals and Botanical Products | Computer Software: Prepackaged Software |
| Sector | Health Care | Technology |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 71.6M | 80.9M |
| IPO Year | 2020 | N/A |
Fundamental Metrics
Financial Performance| Metric | BCAB | GEG |
|---|---|---|
| Price | $0.31 | $2.41 |
| Analyst Decision | Hold | |
| Analyst Count | 3 | 0 |
| Target Price | ★ $1.00 | N/A |
| AVG Volume (30 Days) | ★ 2.0M | 83.4K |
| Earning Date | 11-13-2025 | 02-04-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ 0.12 |
| Revenue | N/A | ★ $23,112,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | $21.17 |
| Revenue Growth | N/A | ★ 24.82 |
| 52 Week Low | $0.24 | $1.76 |
| 52 Week High | $1.43 | $3.51 |
Technical Indicators
Market Signals| Indicator | BCAB | GEG |
|---|---|---|
| Relative Strength Index (RSI) | 26.46 | 41.72 |
| Support Level | $0.40 | $2.37 |
| Resistance Level | $0.82 | $2.55 |
| Average True Range (ATR) | 0.11 | 0.09 |
| MACD | -0.04 | -0.00 |
| Stochastic Oscillator | 0.15 | 22.73 |
Price Performance
Historical ComparisonAbout BCAB BioAtla Inc.
BioAtla Inc is a clinical-stage biopharmaceutical company. The company is engaged in the development of a novel class of specific and selective antibody-based therapeutics for the treatment of solid tumor cancer. Its pipeline products comprise mecbotamab vedotin (BA3011), ozuriftamab vedotin (BA3021), and evalstotug (BA3071), and its Phase 1 clinical trial of BA3182 (CAB-EpCAM x CAB-CD3) and Bispecific antibody programs.
About GEG Great Elm Group Inc.
Great Elm Group Inc operates as an alternative asset manager focused on growing a scalable and diversified portfolio of long-duration and permanent capital vehicles across credit, real estate, specialty finance, and other alternative strategies. Along with its subsidiaries, it manages Great Elm Capital Corp, a publicly traded business development company, and Monomoy Properties REIT, LLC, an industrial-focused real estate investment trust, in addition to other investments.